Lansoprazole: Difference between revisions
ClaireLewis (talk | contribs) |
Ostermayer (talk | contribs) (Prepared the page for translation) |
||
| Line 1: | Line 1: | ||
<languages/> | |||
<translate> | |||
==Administration== | ==Administration== | ||
*Type: [[PPI]] | |||
*Type: [[Special:MyLanguage/PPI|PPI]] | |||
*Dosage Forms: Capsule and Tablet; 15mg & 30mg | *Dosage Forms: Capsule and Tablet; 15mg & 30mg | ||
*Routes of Administration: oral, IV | *Routes of Administration: oral, IV | ||
*Common Trade Names: Prevacid | *Common Trade Names: Prevacid | ||
==Adult Dosing== | ==Adult Dosing== | ||
*15-30mg daily | *15-30mg daily | ||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*Age 1-11 years, weight <30kg: 15mg daily | *Age 1-11 years, weight <30kg: 15mg daily | ||
*Age >1 year, weight >30kg: 15-30mg daily | *Age >1 year, weight >30kg: 15-30mg daily | ||
==Special Populations== | ==Special Populations== | ||
*[[Drug Ratings in Pregnancy|Pregnancy Rating]]: B | |||
*[[Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out | *[[Special:MyLanguage/Drug Ratings in Pregnancy|Pregnancy Rating]]: B | ||
*[[Special:MyLanguage/Lactation risk categories|Lactation risk]]: Infant risk cannot be ruled out | |||
*Renal dosing: no adjustment | *Renal dosing: no adjustment | ||
*Hepatic dosing: if severe, consider dose reduction | *Hepatic dosing: if severe, consider dose reduction | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
==Adverse Reactions== | ==Adverse Reactions== | ||
===Serious=== | ===Serious=== | ||
*C. difficile diarrhea | *C. difficile diarrhea | ||
*SJS/TEN | *SJS/TEN | ||
| Line 28: | Line 44: | ||
*Fracture | *Fracture | ||
*Hypomagnesemia | *Hypomagnesemia | ||
===Common=== | ===Common=== | ||
*Abdominal pain, diarrhea, nausea, constipation | *Abdominal pain, diarrhea, nausea, constipation | ||
*Headache | *Headache | ||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: 1.5-3 hours | *Half-life: 1.5-3 hours | ||
*Metabolism: Hepatic | *Metabolism: Hepatic | ||
*Excretion: Mostly biliary/fecal | *Excretion: Mostly biliary/fecal | ||
==Mechanism of Action== | ==Mechanism of Action== | ||
*Inhibits gastric parietal cell H+/K+ proton pump, leading to decreased gastric acid secretion | *Inhibits gastric parietal cell H+/K+ proton pump, leading to decreased gastric acid secretion | ||
==Comments== | ==Comments== | ||
==See Also== | ==See Also== | ||
*[[PPI]] | |||
*[[Special:MyLanguage/PPI|PPI]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
[[Category:GI]] | [[Category:GI]] | ||
</translate> | |||
Latest revision as of 23:16, 4 January 2026
Administration
- Type: PPI
- Dosage Forms: Capsule and Tablet; 15mg & 30mg
- Routes of Administration: oral, IV
- Common Trade Names: Prevacid
Adult Dosing
- 15-30mg daily
Pediatric Dosing
- Age 1-11 years, weight <30kg: 15mg daily
- Age >1 year, weight >30kg: 15-30mg daily
Special Populations
- Pregnancy Rating: B
- Lactation risk: Infant risk cannot be ruled out
- Renal dosing: no adjustment
- Hepatic dosing: if severe, consider dose reduction
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- C. difficile diarrhea
- SJS/TEN
- Rhabdomyolysis
- Interstitial nephritis
- Fracture
- Hypomagnesemia
Common
- Abdominal pain, diarrhea, nausea, constipation
- Headache
Pharmacology
- Half-life: 1.5-3 hours
- Metabolism: Hepatic
- Excretion: Mostly biliary/fecal
Mechanism of Action
- Inhibits gastric parietal cell H+/K+ proton pump, leading to decreased gastric acid secretion